©The Author(s) 2025.
World J Exp Med. Dec 20, 2025; 15(4): 110890
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.110890
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.110890
Table 1 Characteristics of patients with breast cancer
| Breast cancer characteristics | n (%) |
| Т stage | |
| Тin situ | 4 (2.7) |
| Т1в | 11 (7.5) |
| Т1с | 89 (60.1) |
| Т2 | 44 (29.7) |
| N stage | |
| N0 | 81 (54.7) |
| N1 | 47 (31.8) |
| N2 | 16 (10.8) |
| N3 | 4 (2.7) |
| Clinical stage | |
| 0 | 4 (2.7) |
| I (IA) | 53 (35.8) |
| IIA | 55 (37.2) |
| IIB | 17 (11.5) |
| IIIA | 15 (10.1) |
| IIIB | 4 (2.7) |
| Histology | |
| Intraductal | 4 (2.7) |
| Ductal | 134 (90.5) |
| Lobular | 2 (1.4) |
| Others | 8 (5.4) |
| Tumor grade (G) | |
| G1 | 16 (10.8) |
| G2 | 89 (60.1) |
| G3 | 43 (29.1) |
| Estrogen receptor status | |
| negative | 16 (10.8) |
| positive | 132 (89.2) |
| Progesterone receptor status | |
| Negative | 41 (27.7) |
| Positive | 107 (72.3) |
| HER2 status | |
| Negative | 128 (85.5) |
| Positive | 20 (14.5) |
| Breast cancer molecular biological subtype | |
| Luminal A | 56 (37.8) |
| Luminal B HER2- | 66 (44.6) |
| Luminal B HER2+ | 10 (6.8) |
| Nonluminal HER2+ | 10 (6.8) |
| Triple negative breast cancer | 6 (4.0) |
- Citation: Senchukova MA, Zubareva EY, Saidler NV, Krivolapova LV. Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant. World J Exp Med 2025; 15(4): 110890
- URL: https://www.wjgnet.com/2220-315x/full/v15/i4/110890.htm
- DOI: https://dx.doi.org/10.5493/wjem.v15.i4.110890